<DOC>
	<DOCNO>NCT00707798</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity pneumococcal vaccine young adult . Subjects vaccinate twice interval two month .</brief_summary>
	<brief_title>Evaluation Pneumococcal Vaccine Formulations Young Adults</brief_title>
	<detailed_description>This amendment due - The addition secondary endpoint safety . The collection data related secondary safety endpoint already plan correspond statistical analysis describe statistical section . - The addition exclusion criterion regard administration immunoglobulin blood product . It already include elimination criterion section . It impact immunogenicity .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol ( e.g. , completion diary card , return followup visit ) enrol study . A male female , include , 18 40 year old time first vaccination . Written inform consent obtain subject . Free obvious health problem establish medical history , clinical examination clinical laboratory assessment enter study . If subject female , childbearing potential , agree use adequate contraception become pregnant duration study . Previous vaccination Streptococcus pneumoniae . Vaccination diphtheria/tetanus toxoid within one month precede first dose study vaccine . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period participation another pharmaceutical/vaccine study . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day first dose study vaccine , exception influenza vaccine administer &gt; 7 day precede &gt; 7 day follow vaccine dose ( collection 7day safety data ) . Bacterial pneumonia within 3 year prior 1st vaccination . Invasive pneumococcal disease ( IPD ) within 3 year prior 1st vaccination . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History thrombocytopenia bleed disorder . History reaction allergic disease likely exacerbate component vaccine . Current serious neurologic mental disorder . Inflammatory process know chronic active infection ( e.g . Hepatitis B , C ) . All past current malignancy ( exclude nonmelanic skin cancer ) lymphoproliferative disorder . Acute disease time enrolment/vaccination . Physical examination positive acrocyanosis , jaundice , splenomegaly . Acute chronic , clinically significant anaemia , pulmonary , cardiovascular , hematologic , hepatic renal functional abnormality , determine physical examination laboratory screening test , discretion investigator . Laboratory evidence haematological abnormality . Laboratory evidence biochemical abnormality Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . History chronic alcohol consumption and/or drug abuse . Other condition principal investigator judge may interfere study finding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Young adult</keyword>
	<keyword>Pneumococcal vaccine ,</keyword>
	<keyword>Streptococcus pneumoniae ,</keyword>
</DOC>